GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index; 43 of the 99 sources its claims cite were checked for support.
Abstract
Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being largely dependent on the induction of weight loss. In more recent years, the role of this peptide beyond metabolism has progressively been explored, including its impact on kidney physiology and kidney clinical outcomes in people with obesity with or without diabetes. Indeed, despite only modest expression of the GLP-1 receptor in the kidney, the renoprotective actions of GLP-1 and its receptor agonists have become an area of intensive investigation. This Review appraises the current status of GLP-1 peptide and its receptor agonists and focuses on the preclinical as well as recent seminal clinical findings defining the kidney benefits conferred by GLP-1 receptor agonist treatment in people living with type 2 diabetes and obesity.
Overview
CoChat Summary
## TL;DR
This review summarizes evidence that GLP-1 receptor agonists have kidney benefits in type 2 diabetes and obesity, with effects seen in albuminuria, eGFR decline, and hard kidney outcomes. It also reviews proposed mechanisms and notes that benefits may be partly indirect through improvements in glycemia, weight, blood pressure, and cardiovascular function.
## Key findings
- In cardiovascular outcome trials, GLP-1 receptor agonists consistently reduced urinary albumin-to-creatinine ratios by 20%–40% and reduced new-onset macroalbuminuria in people with T2D.
- In the dedicated FLOW trial, 3,533 participants with T2D and CKD were randomized to semaglutide 1.0 mg weekly or placebo; semaglutide lowered the risk of the primary composite kidney outcome by 24%, the kidney-specific components by 21%, and reduced annual eGFR decline by 1.16 mL/min/1.73 m² versus placebo.
- In SELECT, among participants without diabetes, semaglutide reduced the composite kidney endpoint by 22%; at 104 weeks, eGFR declined less with semaglutide (–0.86 mL/min/1.73 m²) than with placebo (–1.61 mL/min/1.73 m²).
- In SMART, semaglutide 2.4 mg weekly reduced UACR by 52% at 24 weeks in people with overweight/obesity and non-diabetic CKD; a post hoc analysis of SURMOUNT-1 also found tirzepatide reduced UACR in overweight/obese people without T2D.
## Methods
- This is a Review article that appraises preclinical, human physiology, and clinical trial evidence on GLP-1 receptor agonists and kidney outcomes in T2D and obesity.
- The evidence base includes CVOTs, the FLOW kidney outcome trial, obesity/CKD trials such as SELECT and SMART, and mechanistic studies using kidney biopsy, single-cell sequencing, and multiparametric MRI.
- The article synthesizes findings from randomized trials, post hoc and prespecified secondary analyses, and preclinical/physiologic studies rather than presenting original study data.
## Limitations
- The review states that earlier CVOT kidney analyses did not specifically include patients with kidney disease, and the number of hard kidney outcomes was too low to make definitive conclusions.
- It notes that the GLP-1 receptor is only modestly expressed in the kidney, and the precise mechanism of kidney benefit remains uncertain.
- Evident from the text: several mechanistic conclusions are based on heterogeneous studies with inconsistent results across human physiology experiments, and some cited findings are post hoc or from secondary endpoints rather than primary kidney-outcome trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
39 Valid · 0 Not valid · 46 Not checked · 28 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“For example, the effects of GLP-1 receptor agonists on blood pressure appear to be rather modest, as recently summarized (21), and are not in line with kidney outcomes observed with other agents that provide a similar reduction in blood pressure.”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Modulation of kidney risk factors underlying renoprotective effects
What the sources say
- Supportedcites [21] matched to “The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension” (2024) source
The “BP lowering effects with GLP1-RAs” section reports small systolic blood-pressure reductions, including 0.8 mm Hg with lixisenatide and 1.2 mm Hg with liraglutide. These figures support the cited characterization of the blood-pressure effects as modest. The citation is attached to that characterization, not to the citing authors’ subsequent comparison with kidney outcomes. (LLM, conf=0.91)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A recent meta-analysis confirmed little heterogeneity in terms of outcomes in the FLOW trial and in the relevant CVOTs (16).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Renoprotective effects of GLP-1 receptor agonists: clinical trials
What the sources say
- Partly supportedcites [16] matched to “Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials” (2025) sourceExperimental — accuracy not yet measured
The Discussion reports 0% heterogeneity for kidney failure across trials, including FLOW, and the Cardiovascular Outcomes section says MACE treatment effects were consistent across trials. But the reported MACE I² was 49.75% in participants with type 2 diabetes—near the paper’s threshold for moderate heterogeneity—and the paper reports significant heterogeneity for nonfatal myocardial infarction by diabetes status. Thus, “little heterogeneity” is supported for some outcomes, not outcomes generally. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, statistical correction for changes in body weight did not attenuate the albuminuria-lowering effects of GLP-1 receptor agonists in the CVOTs (23).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Modulation of kidney risk factors underlying renoprotective effects
What the sources say
- Partly supportedcites [23] matched to “Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis” (2021) sourceExperimental — accuracy not yet measured
The Results report that body weight mediated 9% of the composite kidney benefit in LEADER and none in SUSTAIN 6; the Discussion concludes that body weight was not an important mediator in either trial. The Methods define that outcome as including, but not limited to, new-onset macroalbuminuria. The paper therefore supports the broad point about kidney benefit, but it does not report a weight-corrected analysis of albuminuria lowering specifically, and the claim’s unqualified ‘did not attenuate’ overlooks the 9% estimate in LEADER. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Overall, between 5% and 10% of subjects stopped treatment in GLP-1 receptor agonist trials because of side effects (17).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Renoprotective effects of GLP-1 receptor agonists: clinical trials
What the sources say
- Partly supportedcites [17] matched to “Safety of Semaglutide” (2021) sourceExperimental — accuracy not yet measured
The Gastrointestinal (GI) Adverse Effects section says GI complaints caused discontinuation in semaglutide phase-3 trials at rates up to 12%, and estimates that approximately 10% of patients discontinue semaglutide because of GI complaints using trial and real-world data. It does not establish a 5%–10% discontinuation range across GLP-1 receptor agonist trials generally. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The pro-oxidant enzyme NAD(P)H oxidase 4 (NOX4) has been shown to promote kidney injury (60), and in mice its expression can be attenuated by treatment with exendin-4 (61).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Postulated direct renoprotective effects of GLP-1 receptor agonists: preclinical evidence In order to define the intrakidney mode of action of GLP-1 receptor agonists, numerous preclinical studies have been performed, predominantly, but not exclusively, in models of DKD. Findings from some of these models have been difficult to interpret since in certain studies the GLP-1 receptor agonists concomitantly affected glucose homeostasis, which is itself usually associated with reduced kidney injury, independent of the mode of glucose lowering. However, one of the earliest studies, performed more than 15 years ago, administered the GLP-1 receptor agonist exendin-4 to db/db mice, a model of T2D (56). Indeed, this agonist was associated with reduced kidney injury. There were modest effects on glucose tolerance without a major effect on fasting glucose concentrations or glycated hemoglobin. These early findings provided initial critical evidence that GLP-1 analogs could potentially be renoprotective, independent of their effects on blood glucose concentrations. To further explore such a possibility, a subsequent preclinical study was performed in insulin-deficient streptozotocin (STZ) diabetic rats with exendin-4 (57). In that study, exendin-4 not only ameliorated albuminuria but conferred kidney structural benefits including reduced glomerular hypertrophy and mesangial matrix expansion in the absence of an effect on body weight, blood pressure, or circulating glucose concentrations. Concomitant effects including reduced kidney inflammation and fibrosis were also observed. This effect on macrophage infiltration has become one of the most prominent features of GLP-1 receptor agonism, as demonstrated in numerous subsequent experimental studies. To further define how GLP-1 receptor agonists act in the kidney at a molecular level, researchers have explored various pathways implicated in kidney injury particularly in the setting of diabetes. DKD is considered to occur as a result of an interplay between metabolic and hemodynamic factors (58), with many of the putative pathways leading to injury having already been delineated (59). Therefore, what have been of particular interest are the effects of GLP-1 on these clearly defined pathways that promote kidney injury, such as oxidative stress, fibrosis via enhanced prosclerotic factor action, and inflammation. The pro-oxidant enzyme NAD(P)H oxidase 4 (NOX4) has been shown to promote kidney injury (60), and in mice its expression can be attenuated by treatment with exendin-4 (61). This effect on renal NOX4 was further examined in STZ diabetic rats treated with liraglutide (62). In that study, GLP-1 agonist treatment led to a reduction in oxidative stress, as assessed by measurement of urinary 8-hydroxy-2-deoxyguanosine and renal dihydroethidium staining. To determine whether the reduction in oxidative stress was mediated directly by GLP-1 receptor activation, complementary in vitro studies in human mesangial cells were performed. Liraglutide inhibited NOX4 enzymatic activity, and this effect could be blocked by incubation with a protein kinase inhibitor or an adenylate cyclase inhibitor (62). Such effects are consistent with a role for the G protein–coupled GLP-1 receptor.
What the sources say
- Supportedcites [60] matched to “Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic Nephropathy” (2014) source
The Abstract reports that deleting Nox4 protected diabetic mice from glomerular injury and identifies Nox4 as a source of ROS responsible for kidney injury in diabetes. This supports the cited claim that NOX4 has been shown to promote kidney injury; the separate exendin-4 claim is attributed to another citation. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
79 more claims · 22 with their cited sources checked
Create a free account to see all 113 claims and to verify the 12 references still open.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 2
- Probably not a substantial claim. 6
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“In the SELECT trial, 2.4 mg semaglutide weekly or placebo was administered to over 16,000 patients with overweight/obesity and established cardiovascular disease (85).”
InfluentialThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GLP-1’s actions to improve glucose metabolism are additionally driven by the reduction of hyper-glucagonemia (5).”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 also plays a key role in the regulation of body weight via various well-characterized mechanisms, including delayed gastric emptying and intestinal transit, and actions in the central nervous system that reduce appetite by stimulating satiety, in particular related to hedonic feeding (6, 7).”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 9×
“Preliminary data point toward beneficial effects of GIP agonism, as reported in findings from the SURPASS program that tirzepatide reduced UACR and slowed down eGFR declined in comparison with both placebo (53) and comparator drugs including insulin glargine (74, 75).”
InfluentialMacrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033 · cited 1×
“There is also increasing evidence that these two macrophage populations produce cytokines and chemokines that can create a feed-forward cycle to accelerate intrarenal inflammation in various kidney diseases, including in diabetes (65).”
Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz, M. J. (2002) · JAMA · doi:10.1001/jama.288.20.2579 · Cited by 1,002 · cited 1×
“DKD is considered to occur as a result of an interplay between metabolic and hemodynamic factors (58), with many of the putative pathways leading to injury having already been delineated (59).”
Targeting the progression of chronic kidney disease
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0248-y · Cited by 979 · cited 1×
“Both kidney cells and recruited immune cells of the innate (M1 macrophages) and the adaptive (CD4 + and CD8 + T cells) immune systems produce proinflammatory factors that damage the kidney (42).”
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
Anderson, S., Meyer, T. W., Rennke, H. G., & Brenner, B. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112013 · Cited by 932 · cited 7×
“A prespecified secondary analysis of SELECT participants without diabetes showed that semaglutide reduced the composite kidney endpoint by 22% (86), with 75% of participants on RAAS blocker therapy at baseline.”
InfluentialThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 1×
“…receptor agonists act directly on the kidney despite very low levels of expression of the only known GLP-1 receptor, which was cloned more than 30 years ago (64), remains a major question, in part due to the limited ability to accurately measure GLP-1 receptor protein expression in the kidney.”
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887 · cited 2×
“Although a generally accepted definition is lacking, glomerular hyperfiltration has been defined as a GFR above 135 mL/min/1.73 m 2 , corresponding to two standard deviations above mean GFR in healthy individuals (34).”
InfluentialPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742 · cited 1×
“Diabetes remains the major cause of kidney failure worldwide, representing in many countries over 50% of individuals with chronic kidney disease (CKD) who require kidney replacement therapy, specifically dialysis or transplantation (1, 2).”
Self-citationThe Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648 · cited 1×
“In people with DKD, the once-weekly GLP-1 receptor agonist dulaglutide increased mGFR (37), although semaglutide appeared to initially reduce eGFR (15).”
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597 · cited 1×
“Indeed, increased urinary sodium excretion and increased urine volume induced by GLP-1 peptide and its receptor agonists have been confirmed in rodents (25), healthy volunteers (26, 27), insulin-resistant obese males (28, 29), and patients with T2D during acute infusion studies (30).”
The kidney in heart failure: an update
Damman, K., & Testani, J. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv010 · Cited by 519 · cited 1×
“Moreover, improvements in cardiac function resulting from treatment with GLP-1 receptor agonists may also contribute to the favorable kidney outcomes seen with these treatments by improving tissue perfusion (20).”
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease
de Vries, A. P. J., Ruggenenti, P., Ruan, X. Z., Praga, M., Cruzado, J. M., Bajema, I. M., D'Agati, V. D., Lamb, H. J., Barlovic, D. P., Hojs, R., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70065-8 · Cited by 500 · cited 1×
“…increased per-irenal fat (46) and hilar fat (47) have been linked to CKD. Proposed mechanisms include physical compression of vessels and nerves, induction of glomerular hyperfiltration (48), and activation of the RAAS as well as stimulation of inflammation by local release of cytokines (49).”
Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator
Ziyadeh, F. N. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093460.24823.5b · Cited by 463 · cited 2×
“Fibrosis is a key pathological hallmark of DKD, and a major role has been identified for prosclerotic growth factors such as TGF-β (68).”
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · cited 2×
“Indeed, increased urinary sodium excretion and increased urine volume induced by GLP-1 peptide and its receptor agonists have been confirmed in rodents (25), healthy volunteers (26, 27), insulin-resistant obese males (28, 29), and patients with T2D during acute infusion studies (30).”
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423 · cited 2×
“Although the triple agonist retatrutide has been demonstrated to be a powerful agent in the setting of diabetes (78) and/or obesity (77), the kidney effects are poorly characterized.”
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · cited 3×
“This rapid excretion occurred independent of changes in the levels of circulating regulators of plasma volume, including atrial natriuretic peptide (ANP) and aldosterone, and a similar phenomenon has also been suggested for the excretion of electrolytes including potassium (18).”
InfluentialKodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · cited 2×
“For example, exendin-4 inhibited the generation of the adhesion molecule ICAM-1 in these endothelial cells, and this effect could be blocked by a GLP-1 receptor antagonist (57).”
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
Cooper, M. E. (2001) · Diabetologia · doi:10.1007/s001250100000 · Cited by 375 · cited 1×
“DKD is considered to occur as a result of an interplay between metabolic and hemodynamic factors (58), with many of the putative pathways leading to injury having already been delineated (59).”
Self-citationGarofalo, C., Borrelli, S., Minutolo, R., Chiodini, P., De Nicola, L., & Conte, G. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.013 · Cited by 363 · cited 1×
“Indeed, obesity, often present in people with T2D, is also a major risk factor for CKD development (4), as are associated conditions such as elevated blood pressure and dyslipidemia.”
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363 · cited 1×
“In addition, parenchymal lipid deposition may induce lipotoxicity (50) through the formation of toxic metabolites including ceramides and diacylglyceride that hamper the function of multiple kidney cell types, including podocytes (51).”
Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00271-7 · Cited by 359 · cited 3×
“The first clinical evidence for beneficial effects of GLP-1 receptor agonists came from the cardiovascular outcome trials (CVOTs) that were conducted with these agents, where kidney endpoints were collected as secondary or exploratory endpoints.”
Fatty Kidney, Hypertension, and Chronic Kidney Disease: The Framingham Heart Study
Foster, M. C., Hwang, S.-J., Porter, S. A., Massaro, J. M., Hoffmann, U., & Fox, C. S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.175315 · Cited by 356 · cited 1×
“Specifically, increased per-irenal fat (46) and hilar fat (47) have been linked to CKD. Proposed mechanisms include physical compression of vessels and nerves, induction of glomerular hyperfiltration (48), and activation of the RAAS as well as stimulation of inflammation by local release of…”
Jha, J. C., Gray, S. P., Barit, D., Okabe, J., El-Osta, A., Namikoshi, T., Thallas-Bonke, V., Wingler, K., Szyndralewiez, C., Heitz, F., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013070810 · Cited by 352 · cited 1×
“The pro-oxidant enzyme NAD(P)H oxidase 4 (NOX4) has been shown to promote kidney injury (60), and in mice its expression can be attenuated by treatment with exendin-4 (61).”
Self-citationSmits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Self-citation(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70156-1 · Cited by 319
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 1×
“Similar antiinflammatory effects of GLP-1 have been reported in human macrophage cell lines (66), and systemic effects of GLP-1 agonists on macrophage infiltration have been previously reported (67).”
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306 · cited 1×
“Preliminary data point toward beneficial effects of GIP agonism, as reported in findings from the SURPASS program that tirzepatide reduced UACR and slowed down eGFR declined in comparison with both placebo (53) and comparator drugs including insulin glargine (74, 75).”
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · cited 2×
“Early studies suggested more widespread expression of the GLP-1 receptor on a range of cell populations within the kidney using antibodies that were subsequently considered to be nonspecific (11).”
Muskiet, M. H. A., Tonneijck, L., Huang, Y., Liu, M., Saremi, A., Heerspink, H. J. L., & van Raalte, D. H. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30268-7 · Cited by 259 · cited 2×
“%) and body weight (–0.7 kg) (13).”
InfluentialShaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255 · cited 1×
“In these studies, GLP-1 receptor agonist treatment consistently reduced urinary albumin-to-creatinine ratios (UACRs) by 20%–40% and new-onset macroalbuminuria in people with T2D (12, 13).”
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03015-5 · Cited by 238 · cited 1×
“A prespecified secondary analysis of SELECT participants without diabetes showed that semaglutide reduced the composite kidney endpoint by 22% (86), with 75% of participants on RAAS blocker therapy at baseline.”
le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00356-x · Cited by 237 · cited 1×
“Glucagon agonism is currently being considered as a component of newer agents including as a dual agonist with GLP-1 (76) and as a triple agonist with GLP-1 and GIP (77, 78).”
Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232 · cited 3×
“Lira-glutide inhibited NOX4 enzymatic activity, and this effect could be blocked by incubation with a protein kinase inhibitor or an adenylate cyclase inhibitor (62).”
Skov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228 · cited 1×
“Indeed, increased urinary sodium excretion and increased urine volume induced by GLP-1 peptide and its receptor agonists have been confirmed in rodents (25), healthy volunteers (26, 27), insulin-resistant obese males (28, 29), and patients with T2D during acute infusion studies (30).”
Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218 · cited 1×
“However, one of the earliest studies, performed more than 15 years ago, administered the GLP-1 receptor agonist exendin-4 to db/db mice, a model of T2D (56).”
Wu, L. L., Cox, A., Roe, C. J., Dziadek, M., Cooper, M. E., & Gilbert, R. E. (1997) · Kidney International · doi:10.1038/ki.1997.214 · Cited by 209
Self-citationGlucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., & Takeya, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.086 · Cited by 208 · cited 1×
“Similar antiinflammatory effects of GLP-1 have been reported in human macrophage cell lines (66), and systemic effects of GLP-1 agonists on macrophage infiltration have been previously reported (67).”
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204 · cited 1×
“In people with T1D, GLP-1 infusion counteracted hypo-and hyperglycemia-induced increases in the inflammation markers IL-6 and soluble intercellular adhesion molecule-1 (sICAM-1) (45).”
Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids
Sieber, J., Lindenmeyer, M. T., Kampe, K., Campbell, K. N., Cohen, C. D., Hopfer, H., Mundel, P., & Jehle, A. W. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00196.2010 · Cited by 203 · cited 1×
“In addition, parenchymal lipid deposition may induce lipotoxicity (50) through the formation of toxic metabolites including ceramides and diacylglyceride that hamper the function of multiple kidney cell types, including podocytes (51).”
Hesp, A. C., Schaub, J. A., Prasad, P. V., Vallon, V., Laverman, G. D., Bjornstad, P., & van Raalte, D. H. (2020) · Kidney International · doi:10.1016/j.kint.2020.02.041 · Cited by 202 · cited 3×
“It remains to be determined how GLP-1 confers its kidney benefits, as the only GLP-1 receptor that has been identified has limited expression in the kidney (8).”
InfluentialPruijm, M., Milani, B., Pivin, E., Podhajska, A., Vogt, B., Stuber, M., & Burnier, M. (2018) · Kidney International · doi:10.1016/j.kint.2017.10.020 · Cited by 200 · cited 1×
“In people with CKD, lower oxygen availability was associated with more rapid kidney function decline in comparison with people with higher oxygen availability (39).”
Sourris, K. C., Ding, Y., Maxwell, S. S., Al-sharea, A., Kantharidis, P., Mohan, M., Rosado, C. J., Penfold, S. A., Haase, C., Xu, Y., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.029 · Cited by 143 · cited 3×
“A recent study demonstrated that deletion of the GLP-1 receptor using knockout technology was associated with renal injury in association with macrophage infiltration (63).”
Self-citationInflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications
Donate-Correa, J., Ferri, C. M., Sánchez-Quintana, F., Pérez-Castro, A., González-Luis, A., Martín-Núñez, E., Mora-Fernández, C., & Navarro-González, J. F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.628289 · Cited by 140 · cited 14×
“It has been well established that in both type 1 diabetes (T1D) and T2D, a chronic low-grade inflammatory state contributes to DKD, in part due to hyperglycemic insults.”
InfluentialTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133 · cited 1×
“Furthermore, it remains controversial whether agonists or antagonists of the GIP receptor are the optimal approach in the management of metabolic disorders (73).”
Tubuloglomerular Feedback and the Control of Glomerular Filtration Rate
Vallon, V. (2003) · Physiology · doi:10.1152/nips.01442.2003 · Cited by 131 · cited 3×
“These cells are critical regulators of glomerular perfusion and pressure and are intimately involved in a physiological process known as tubuloglomerular feedback (TGF) (10), which is detailed below.”
Glucagon-Like Peptide-1 Is Involved in Sodium and Water Homeostasis in Humans
Gutzwiller, J.-P., Hruz, P., Huber, A. R., Hamel, C., Zehnder, C., Drewe, J., Gutmann, H., Stanga, Z., Vogel, D., & Beglinger, C. (2006) · Digestion · doi:10.1159/000094334 · Cited by 127 · cited 1×
“Indeed, increased urinary sodium excretion and increased urine volume induced by GLP-1 peptide and its receptor agonists have been confirmed in rodents (25), healthy volunteers (26, 27), insulin-resistant obese males (28, 29), and patients with T2D during acute infusion studies (30).”
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127 · cited 13×
“These mice have major kidney abnormalities including enhanced oxidative stress, enhanced activity of the inflammasome, and fibrosis, all features of CKD.”
InfluentialTonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126 · cited 2×
“Indeed, increased urinary sodium excretion and increased urine volume induced by GLP-1 peptide and its receptor agonists have been confirmed in rodents (25), healthy volunteers (26, 27), insulin-resistant obese males (28, 29), and patients with T2D during acute infusion studies (30).”
Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03327-6 · Cited by 120
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14443 · Cited by 120 · cited 3×
“The first clinical evidence for beneficial effects of GLP-1 receptor agonists came from the cardiovascular outcome trials (CVOTs) that were conducted with these agents, where kidney endpoints were collected as secondary or exploratory endpoints.”
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care · doi:10.2337/dc16-1371 · Cited by 113 · cited 1×
“In an uncontrolled study in people with T2D, liraglutide initially lowered eGFR (35), but this result was not confirmed in placebo-controlled studies that assessed mGFR and kidney hemodynamic function by gold-standard tracer methods (36).”
The physiological role of glucagon-like peptide-1 in the regulation of renal function
Farah, L. X. S., Valentini, V., Pessoa, T. D., Malnic, G., McDonough, A. A., & Girardi, A. C. C. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00394.2015 · Cited by 111 · cited 1×
“These effects on urinary volume and sodium excretion could be blocked in mice using a GLP-1 receptor antagonist (31).”
Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., & Liu, J. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193473 · Cited by 110 · cited 1×
“Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below.”
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12601 · Cited by 102 · cited 2×
“Indeed, increased urinary sodium excretion and increased urine volume induced by GLP-1 peptide and its receptor agonists have been confirmed in rodents (25), healthy volunteers (26, 27), insulin-resistant obese males (28, 29), and patients with T2D during acute infusion studies (30).”
Bae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 101 · cited 15×
“These mice have major kidney abnormalities including enhanced oxidative stress, enhanced activity of the inflammasome, and fibrosis, all features of CKD.”
InfluentialChen, X., Mao, Y., Hu, J., Han, S., Gong, L., Luo, T., Yang, S., Qing, H., Wang, Y., Du, Z., et al. (2021) · Diabetes · doi:10.2337/db20-1031 · Cited by 92 · cited 1×
“Specifically, increased per-irenal fat (46) and hilar fat (47) have been linked to CKD. Proposed mechanisms include physical compression of vessels and nerves, induction of glomerular hyperfiltration (48), and activation of the RAAS as well as stimulation of inflammation by local release of…”
le Roux, C. W., Zhang, S., Aronne, L. J., Kushner, R. F., Chao, A. M., Machineni, S., Dunn, J., Chigutsa, F. B., Ahmad, N. N., & Bunck, M. C. (2023) · Obesity · doi:10.1002/oby.23612 · Cited by 91 · cited 1×
“The impact of tirzepatide on clinical kidney outcomes is part of the SURPASS CVOT (T2D patients) and multimorbidity outcomes (people with overweight or obesity without T2D) (91), albeit as secondary endpoints.”
Obesity and the kidney: mechanistic links and therapeutic advances
Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00951-7 · Cited by 91 · cited 1×
“Specifically, GLP-1 receptor agonists favorably influence relevant risk factors for kidney disease, including hyperglycemia, elevated blood pressure, and increased body weight (19).”
Renal sinus fat and renal hemodynamics: a cross-sectional analysis
Spit, K. A., Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Joles, J. A., de Boer, A., & van Raalte, D. H. (2020) · Magnetic Resonance Materials in Physics, Biology and Medicine · doi:10.1007/s10334-019-00773-z · Cited by 83 · cited 1×
“…increased per-irenal fat (46) and hilar fat (47) have been linked to CKD. Proposed mechanisms include physical compression of vessels and nerves, induction of glomerular hyperfiltration (48), and activation of the RAAS as well as stimulation of inflammation by local release of cytokines (49).”
Self-citationCarey, R. M. (1978) · Circulation Research · doi:10.1161/01.res.43.1.19 · Cited by 76 · cited 1×
“The proposals were based on studies in humans showing that in a sodium-depleted state, an oral sodium load is more rapidly excreted by the kidneys than an intravenous sodium load (24).”
Gullaksen, S., Vernstrøm, L., Sørensen, S. S., Ringgaard, S., Laustsen, C., Funck, K. L., Poulsen, P. L., & Laugesen, E. (2023) · Diabetologia · doi:10.1007/s00125-023-05876-w · Cited by 75 · cited 1×
“(41).”
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73 · cited 1×
“In an uncontrolled study in people with T2D, liraglutide initially lowered eGFR (35), but this result was not confirmed in placebo-controlled studies that assessed mGFR and kidney hemodynamic function by gold-standard tracer methods (36).”
Sancar-Bas, S., Gezginci-Oktayoglu, S., & Bolkent, S. (2015) · Growth Factors · doi:10.3109/08977194.2015.1125349 · Cited by 71 · cited 1×
“The pro-oxidant enzyme NAD(P)H oxidase 4 (NOX4) has been shown to promote kidney injury (60), and in mice its expression can be attenuated by treatment with exendin-4 (61).”
He, L., Wong, C. K., Cheung, K. K., Yau, H. C., Fu, A., Zhao, H., Leung, K. M., Kong, A. P., Wong, G. W., Chan, P. K., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12063 · Cited by 70
Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation
Hviid, A. V. R., & Sørensen, C. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00280.2019 · Cited by 69 · cited 1×
“Gene expression studies, as reviewed recently (9), have identified low mRNA levels of the G protein–coupled GLP-1 receptor in numerous kidney cell populations, including endothelial cells, vascular smooth muscle cells, and glomerular epithelial cells (also known as podocytes).”
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12985 · Cited by 62 · cited 1×
“As seen with inhibitors of SGLT2, this increase in urinary sodium excretion is only present acutely (32).”
Influence of glucagon on GFR and on urea and electrolyte excretion: direct and indirect effects
Ahloulay, M., Dechaux, M., Laborde, K., & Bankir, L. (1995) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1995.269.2.f225 · Cited by 59
Tonneijck, L., Muskiet, M. H. A., Blijdorp, C. J., Smits, M. M., Twisk, J. W., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., Hoorn, E. J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00432.2018 · Cited by 57 · cited 1×
“This suggests that the effect involves inhibition of sodium-hydrogen antiporter (NHE3) (33).”
Apperloo, E. M., Tuttle, K. R., Pavo, I., Haupt, A., Taylor, R., Wiese, R. J., Hemmingway, A., Cherney, D. Z. I., Sattar, N., & Heerspink, H. J. L. (2025) · Diabetes Care · doi:10.2337/dc24-1773 · Cited by 53 · cited 3×
“Currently, a number of studies are employing multiparametric kidney MRI to assess the effects of sema-glutide (NCT04865770) (52), tirzepatide (NCT05536804) (53), and retatrutide (NCT05936151) (54) on kidney fat accumulation and link these effects to changes in GFR and albuminuria.”
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0261 · Cited by 53 · cited 1×
“Preliminary data point toward beneficial effects of GIP agonism, as reported in findings from the SURPASS program that tirzepatide reduced UACR and slowed down eGFR declined in comparison with both placebo (53) and comparator drugs including insulin glargine (74, 75).”
Wang, M.-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X.-N., Zhu, Q., Li, C., Li, N., Chen, S., Paredes, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.024 · Cited by 52 · cited 1×
“The importance of glucagon receptors in the kidney has been further explored in mice with kidney-specific glucagon receptor knockout (80).”
Amylin Stimulates Plasma Renin Concentration in Humans
Cooper, M. E., McNally, P. G., Phillips, P. A., & Johnston, C. I. (1995) · Hypertension · doi:10.1161/01.hyp.26.3.460 · Cited by 50 · cited 6×
“A prespecified secondary analysis of SELECT participants without diabetes showed that semaglutide reduced the composite kidney endpoint by 22% (86), with 75% of participants on RAAS blocker therapy at baseline.”
InfluentialSelf-citationPacker, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49 · cited 1×
“Regarding co-agonist treat-ment, tirzepatide was recently shown in a post hoc analysis of the SURMOUNT-1 trial to also reduce UACR in overweight/obese people without T2D (88), and similar benefits for kidney function were shown in subjects with heart failure (89).”
Selvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y.-T., Yu, H., Parkinson, J., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.08.023 · Cited by 49 · cited 13×
“It has been well established that in both type 1 diabetes (T1D) and T2D, a chronic low-grade inflammatory state contributes to DKD, in part due to hyperglycemic insults.”
InfluentialAmylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney
Harris, P. J., Cooper, M. E., Hiranyachattada, S., Berka, J. L., Kelly, D. J., Nobes, M., & Wookey, P. J. (1997) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1997.272.1.f13 · Cited by 47 · cited 1×
“Although this new agent (cagrilintide/semaglutide) has not been addressed from a kidney perspective in clinical studies, it is known that amylin binds to G protein–coupled receptors in kidney and has been reported to influence proximal tubular sodium transport and activate the RAAS (83, 84).”
Self-citationDulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis
Botros, F. T., Gerstein, H. C., Malik, R., Nicolay, C., Hoover, A., Turfanda, I., Colhoun, H. M., & Shaw, J. E. (2023) · Diabetes Care · doi:10.2337/dc23-0231 · Cited by 42 · cited 1×
“Other improvements in surrogate endpoints included a reduction in decline of estimated glomerular filtration rate (eGFR), calculated by slope analysis (14).”
Haddock, B., Kristensen, K. B., Tayyab, M., Larsson, H. B. W., Lindberg, U., Vestergaard, M., Francis, S., Jensen, B. L., Andersen, U. B., & Asmar, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027712 · Cited by 23 · cited 1×
“In a study in which GLP-1 peptide was infused, GLP-1 increased both cortical and medullary perfusion (40).”
A review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 21
Yeung, M. H. Y., Leung, K. L., Choi, L. Y., Yoo, J. S., Yung, S., So, P.-K., & Wong, C.-M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777395 · Cited by 14
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10 · cited 1×
“For example, the effects of GLP-1 receptor agonists on blood pressure appear to be rather modest, as recently summarized (21), and are not in line with kidney outcomes observed with other agents that provide a similar reduction in blood pressure.”
HEERSPINK, H. L., LU, Z., DU, Y., DUFFIN, K. L., COSKUN, T., HAUPT, A., & HARTMAN, M. L. (2024) · Diabetes · doi:10.2337/db24-754-p · Cited by 7 · cited 8×
“Recently, retatrutide was shown to increase eGFR and to reduce UACR (81).”
InfluentialHeerspink, H. J., Friedman, A. N., Bjornstad, P., Raalte, D. H. V., Yang, Z., Stefanski, A., Chigutsa, F. B., Turfanda, I., Bunck, M., & de Oliveira, C. P. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.20233411s141b · Cited by 3
Self-citation
Research works printed but not linked: 3
- Cherney, Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease, Nephrol Dial Transplant
- Brown, 1970, Cleavage of a gastric inhibitory polypeptide with cyanogen bromide and the physiological action of the C-terminal fragment, J Physiol, 210, 52
- Rosenstock, Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes, N Engl J Med
Cited by
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
“Proposed mechanisms include mechanical compression of renal vessels and nerves, induction of glomerular hyper-filtration, activation of the renin–angiotensin–aldosterone system, and promotion of inflammation through local cyto - kine release [26 ].”
Kidney angiopoietin-like protein 4 regulates fibrotic responses in diabetic kidney disease
Srivastava, S. P., Arora, A., Hamed, M., Urval, A., Dupati, A., Xia, S., Yoshida, S., & Inoki, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1803412 · Cited by 1
“GLP-1 RAs and SGLT2is provide cardio-renal protection that differs from renin-angiotensin system inhibition, providing an additional layer of DKD treatment (Colhoun et al., 2024; Cooper and van Raalte, 2025; Fioretto et al., 2016; Bae, 2025).”
Li, J., Liang, J., Zhang, W., He, J., & Ye, X. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01872-6 · Cited by 5
“Notably, the National Medical Products Administration (NMPA) has approved semaglutide for chronic kidney disease (CKD) [40], making it the first GLP-1 RA in China with indications for glycemic control, cardiovascular protection, and renal protection [41].”
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
“These agents slow kidney disease progression, support neuroprotection in neurodegenerative disorders, and semaglutide is approved for chronic kidney disease and metabolic dysfunction-associated steatohepatitis (MASH) based on clinical trial outcomes [127,128].”
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“GLP-1R are the primary and most well-studied incretin receptors in the kidney [208 ].”
Metadata
- Authors
- Cooper, M. E., & van Raalte, D. H.
- Affiliations
- Monash University (AU)
- Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.
- Corresponding author
- Cooper, Mark E.
- ORCID
- Cooper, Mark E.
- Venue
- Journal of Clinical Investigation
- Published
- 2025-11-03
- Volume
- 135
- Issue
- 21
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12578383
- OpenAlex
- W4415854994
- Semantic Scholar
- 5f04c667298e09c33f3fbc24adfb4ab50611f6dd
- Cited by
- 24
- References
- 90
- Citations by year
- 2026: 24
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Eli Lilly and Company
- AstraZeneca
- Monash University
- Nierstichting
- Ministerio de Economía y Competitividad
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- GLP-1 receptor agonists, glucagon-like peptide-1, chronic kidney disease, type 2 diabetes, obesity, renal protection, renal function, insulin resistance, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Obesity, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.